3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
129
Recurrence
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasms, Plasma Cell
15
Neoplasms
12
Lymphoma, Non-Hodgkin
12
Lymphoma
12
Leukemia, Myeloid, Acute
10
Lymphoma, Large B-Cell, Diffuse
9
Neoplasm Metastasis
8
Leukemia
8
Burkitt Lymphoma
8
Immunoglobulin Light-chain Amyloidosis
7
Hodgkin Disease
7
Prostatic Neoplasms
6
Leukemia, Biphenotypic, Acute
5
Lymphoma, B-Cell
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Waldenstrom Macroglobulinemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma, Follicular
3
Hematologic Diseases
3
Colorectal Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Sarcoma
2
Rectal Neoplasms
2
Interventions
Paclitaxel
2
Kidney Transplantation
2
Cyclophosphamide
2
Azacitidine
2
veliparib
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pomalidomide
1
pevonedistat
1
osimertinib
1
mirabegron
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
dabrafenib
1
copanlisib
1
belinostat
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Topotecan
1
Taxes
1
Sitagliptin Phosphate
1
Rituximab
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Methotrexate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Renal Insufficiency
×
Dexamethasone
×
Clear all
NCT01575925
2022-11-04
POM Renal
Celgene
Phase 1
Completed
25 enrolled